AGTC

Sue Washer, President and CEO
Alachua, FL and Cambridge, MA
(NASDAQ: AGTC)
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic, and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. Initially focusing on ophthalmology, our goal is to preserve or hopefully be able to improve vision in some cases. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Our preclinical programs build on our industry-leading AAV manufacturing technology and expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology, and CNS disorders.
www.agtc.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions